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Next-generation sequencing of the hypervariable V3 region of the 16s rRNA gene isolated from serial stool
specimens collected from 31 patients receiving allogeneic stem cell transplantation (SCT) was performed
to elucidate variations in the composition of the intestinal microbiome in the course of allogeneic SCT.
Metagenomic analysis was complemented by strain-speciﬁc enterococcal PCR and indirect assessment of
bacterial load by liquid chromatography-tandem mass spectrometry of urinary indoxyl sulfate. At the time of
admission, patients showed a predominance of commensal bacteria. After transplantation, a relative shift
toward enterococci was observed, which was more pronounced under antibiotic prophylaxis and treatment
of neutropenic infections. The shift was particularly prominent in patients that developed subsequently or
suffered from active gastrointestinal (GI) graft-versus-host disease (GVHD). The mean proportion of
enterococci in post-transplant stool specimens was 21% in patients who did not develop GI GVHD as
compared with 46% in those that subsequently developed GI GVHD and 74% at the time of active GVHD.
Enterococcal PCR conﬁrmed predominance of Enterococcus faecium or both E. faecium and Enterococcus
faecalis in these specimens. As a consequence of the loss of bacterial diversity, mean urinary indoxyl
sulfate levels dropped from 42.5  11 mmol/L to 11.8  2.8 mmol/L in all post-transplant samples and to
3.5  3 mmol/L in samples from patients with active GVHD. Our study reveals major microbiome shifts in the
course of allogeneic SCT that occur in the period of antibiotic treatment but are more prominent in associ-
ation with GI GVHD. Our data indicate early microbiome shifts and a loss of diversity of the intestinal
microbiome that may affect intestinal inﬂammation in the setting of allogeneic SCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Immune responses induced by gastrointestinal (GI)
microﬂora play a key role in the pathophysiology of graft-
versus-host disease (GVHD), as shown almost 40 years ago
by van Bekkum et al.’s demonstration that germ-free animals
do not develop GVHD [1]. However, the exact nature of these
interactions in GVHD remains unclear. Early studies focused
on the ability of bacterial components such as endotoxin
(lipopolysaccharide) to activate macrophages that causeedgments on page 644.
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14.01.030inﬂammation [2,3]. It is now clear, however, that the intes-
tinal microbiome exerts multiple effects that can result in
speciﬁc tolerance to commensal bacteria in healthy in-
dividuals, whereas a loss of microbiome diversity is associ-
ated with a number of inﬂammatory diseases [4,5].
Further evidence for a role of the intestinal microbiome in
GVHDwas suggested by protection from experimental GVHD
by the prophylactic application of probiotic lactobacilli in
mice [6] and by clinical data suggesting that prophylactic use
of ciproﬂoxacin/metronidazole antibiotics may reduce GVHD
[7]. More recently, 16S rRNA gene sequencing has allowed
deeper analysis of intestinal bacterial diversity. In the setting
of experimental stem cell transplantation (SCT), Eriguchi
et al. [8] provided evidence that murine GVHD disrupts the
intestinal microbiome and suggested a loss of Paneth cellsTransplantation.
Figure 1. Box plots of the 10 most variable bacteria in patients pretransplant and post-transplant with and without active GVHD. Data for each bacterium are grouped
according to simultaneous use of antibiotics (no antibiotics or oral ciproﬂoxacin/oral trimethoprim/sulfamethoxazole and oral and systemic antibiotics). Boxes show
the median and lower and upper quartiles, respectively, whereas the ends of the whiskers represent the minimum and maximum of all data after removal of outliers.
The fraction of microbiome shown on the y-axis was iteratively renormalized as follows: For the most prominent bacterium, the absolute fraction is shown. All reads
mapping to this bacteriumwhere removed before calculating the relative fraction of the second most abundant bacterium. For calculating the fraction of the nth most
abundant bacterium, all reads of the n-1 more frequent bacteria were removed.
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nism. In line with this, we analyzed intestinal biopsies from
patients with acute GVHD and observed Paneth cell loss as a
hallmark of GVHD also in patients [9]. Jenq et al. [9] further
conﬁrmed loss of bacterial diversity in GVHD both in
experimental models and in patients receiving allogeneic
SCT.
Here, we used both molecular typing of the microbiome
by pyrosequencing of the hypervariable V3 region of the 16S
rRNA gene and strain-speciﬁc PCR of enterococci and an in-
direct metabolic approach analyzing urinary indoxyl sulfate
(IS), which originates from the degradation of tryptophan to
indole by colonic microbiota followed by microsomal
oxidation to indoxyl and sulfonation, to monitor microbiome
shifts in the course of human allogeneic SCT. We identiﬁed a
major loss of bacterial diversity, which may contribute to
intestinal inﬂammation.METHODS
This study was approved by the Ethics Committee of the University
Medical Center of Regensburg. After provision of informed consent, 31 pa-
tients and 3 donors were enrolled in a prospective study to collect stool
specimens before and after allogeneic SCT. Median age of the patients was
47 (11) years. Underlying diseases were acute myelogenous leukemia
(n¼ 14), acute lymphoblastic leukemia (n¼ 5), lymphoma (n¼ 4), myeloma
and myelodysplastic syndrome (n¼ 3 each), chronic myelogenous leukemia
(n ¼ 1), and aplastic anemia (n ¼ 1). Thirteen patients received grafts from
HLA-identical siblings, whereas 18 received grafts from matched unrelated
donors. Eleven patients received myeloablative conditioning, and 20 pa-
tients received reduced-intensity conditioning. All patients received pro-
phylactic antibiotics (trimethoprim/sulfamethoxazole) starting from
admission until day e1, followed by ciproﬂoxacin/metronidazole [8] from
day 0 until engraftment and empiric or therapeutic antibiotics in the case of
infections. GVHD symptoms were recorded weekly for the ﬁrst 100 days; GI
GVHD was conﬁrmed by endoscopic biopsy.
One hundred ﬁfty-three stool specimenswere collected at aminimum of
3 different time points: before admission until the day of transplantation, at
least once on days 7 to 14 (aplastic period), and on days 21 to 28(engraftment and early GVHD period). In 18 specimens, predominantly in
patients with watery diarrhea in the aplastic period, no bacterial DNA could
be extracted, which reduced the number of stool specimens subjected to
successful 16S rRNA gene sequencing to 135. Later sample collection on a
2-weekly basis and in relation to occurrence of GVHDwas scheduled but was
mainly performed on inpatients.
Stool specimens were frozen at 80C until use. DNA was isolated by
phenol-chloroform extraction, and the concentration was standardized
before ampliﬁcation. The hypervariable V3 region of the 16s rRNA gene was
ampliﬁed as described [10] and sequenced on a 454 GS FLX sequencer
(Roche Diagnostics, Basel, Switzerland) using Gene Sequencing FLX titanium
chemistry, generating on average 20,000 sequence reads per specimen.
Overall taxonomic composition of each stool specimenwas calculated using
the VITCOMIC algorithm 9 [11]. For all DNA samples, additional strain-
speciﬁc PCR of the internal transcribed ribosomal spacer region was per-
formed according toTyrrell et al. [12]. Urinary specimenswere collected on a
weekly basis and frozen at 80C. Liquid chromatography-tandem mass
spectrometry analysis of IS was performed, and results were corrected to
urinary creatinine as described previously [13].
For the given sample size, rigorous statistical inference is prohibited by
the multitude of confounding factors that can affect microbiome readouts in
addition to GVHD. These include the exact combination and dosage of an-
tibiotics, the underlying disease, patient nutrition, diarrhea, day of stool
collection, and more. Hence, to avoid over-interpretation of our data, we
conﬁned ourselves to data description and visualization.
RESULTS
16S rRNA Gene Sequencing
Donors showed an expected distribution of the major
phyla: Actinobacteriacea were lowest with .7%  .4% (arith-
metic mean  standard error), followed by Proteobacteriae,
Bacteroidetes, and Firmicutes with 6.2%  2.0%, 9.1%  5.4%,
and 81.7%  5.6%, respectively. Among the Firmicutes,
enterococci were almost absent, whereas Eubacterium rectale
(42.7% 16.0%), Clostridium phytofermentans (34.8% 20.7%),
and Lactobacillus lactis (9.4%  1.8%) were the most dominant
commensal strains. Patients at the time of admission showed
a comparable distribution with some loss of the dominant
commensal strains and an increase in enterococci to
Figure 2. Box plot of the risk of GI GVHD as a function of relative abundance of enterococci in stool specimens. Boxes show the median and lower and upper quartiles,
respectively, whereas ends of the whiskers represent the 9th percentile and the 91st percentile. Outliers are shown as dots. Because the number of observations per
patients varies substantially, we sampled 10,000 times randomly 2 observations per patient and averaged the number of enterococci. The distribution of risks across
the 10,000 random samples is shown as box plots.
Table 1
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the day of transplant, all patients showed major shifts in the
microbiomewith a predominant increase in the proportion of
enterococci and a complementary decrease in other Firmi-
cutes and phyla (Figure 1, Supplemental Figure 1). In active
GVHD, this shift was most pronounced, with an almost
complete loss of commensal Firmicutes such as Clostridia and
E. rectale, whereas residual commensals were present in pa-
tients without GI GVHD. Beyond day 28, the pattern started to
return to pretransplant patterns in patients without and with
resolving GI GVHD but not in 2 patients who suffered from
ongoing active GI GVHD.
The observed changes indicated 2 factors associated with
microbiome shifts. First, the use of broad-spectrum antibi-
otics, especially ciproﬂoxacin and systemic antibiotics,
resulted in an increase in enterococci and a concomitant
reduction in classical commensal bacteria. The second factor
associated with a further increase in enterococci was GI
GVHD: This was most striking when pretransplant patients
were compared with patients without and with active GI
GVHD as conﬁrmed by histology. Albeit limited by a small
number of samples, the abundance of enterococci in active GI
GVHD was also seen in patients who did not receive antibi-
otics (Figure 1). The potential association of GI GVHD with
enterococcal ﬂora is also suggested by the increased fre-
quency of GI GVHD in patients with enterococcal abundance
exceeding 20% (Figure 2).Positive Enterococcal PCR in Post-Treatment Samples in Relation to Later
Occurrence or Active GI GVHD
Post-SCT Group No
Enterococci
E. faecalis
Only
E. faecium
Only
Both
Never GI GVHD 19 (44%) 2 (5%) 18 (42%) 4 (9%)
Subsequent GI
GVHD
3 (11%) 3 (11%) 8 (30%) 13 (48%)
Active GI GVHD 1 (9%) 2 (19%) 4 (36%) 4 (36%)Increase in Enterococci Is Conﬁrmed by Strain-Speciﬁc
PCR
Because the applied 16s rRNA gene analysis did not
distinguish between enterococcal strains, strain-speciﬁc PCR
was performed to determine the contribution of both En-
terococcus faecalis and Enterococcus faecium. E. faecium wassigniﬁcantly more frequent post-transplant, especially in pa-
tients with subsequent or active GI GVHD (Table 1). Antibiotic
treatment mainly enhanced E. faecalis and to a lesser extent
E. faecium (Table 2). Although enterococcal PCR does not allow
absolute quantiﬁcation of bacterial load, copy numbers for
E. faeciumwere signiﬁcantly increased in patients with active
GI GVHD as compared with post-transplant patients without
GVHD.IS as an Indirect Marker of Bacterial Diversity
We next tested whether IS could be used as an indirect
marker of bacterial load. As shown in Figure 3, urinary IS
levels dropped in the period of neutropenia (which is also
the period of prophylactic and therapeutic use of antibiotics)
and recovered partially thereafter. Mean post-treatment
levels were lower in patients with GI GVHD but not on an-
tibiotics and in patients on antibiotics but lowest in patients
with GI GVHD and under antibiotic treatment (Table 3).
Finally, we analyzed the correlation of IS levels with the
most prominent speciﬁc microbiota. There was a negative
correlation with enterococci (.350, P < .000) and a positive
correlation with colonic commensals such as E. rectale (.222,
P ¼ .018) and Clostridium phytofermentalis (.222, P ¼ .014),
Table 2
Antibiotic Treatment and Positive Enterococcal PCR
No
Enterococci
E. faecalis
Only
E. faecium
Only
Both
Pre-SCT
Without
antibiotics
14 (58%) 3 (13%) 6 (25%) 1 (4%)
With antibiotics 4 (27%) 4 (27%) 5 (33%) 2 (13%)
Post-SCT
Without
antibiotics
8 (44%) 0 (0%) 7 (39%) 3 (17%)
With antibiotics 16 (25%) 7 (11%) 23 (36%) 18 (28%)
E. Holler et al. / Biol Blood Marrow Transplant 20 (2014) 640e645 643whereas other bacteria such as lactobacilli failed to show any
correlation.
DISCUSSION
In our study, we used 2 direct and 1 indirect approach to
monitor changes in stool microbiome in the early course of
allogeneic SCT. Whereas pretransplant patients had a distri-
bution of bacteria that was quite comparable with healthy
normal donors, major changes occurred during the neu-
tropenic period and after engraftment. As shown by the
comparison of 16S rRNA gene sequences in patients with and
without use of antibiotics, the observed loss of commensal
bacteria and the increase in enterococci in this period reﬂect
the administration of both oral ciproﬂoxacin and systemic
broad-spectrum antibiotics. Suppression of commensal ﬂora
by clinical use of antibiotics has been shown, and a speciﬁc
mechanism for overgrowth of enterococci has been sug-
gested [14]: Commensal bacteria are important inducers of
antimicrobial peptides (AMPs) to maintain a diverse
composition of the microbiome. After prolonged use ofFigure 3. Time courses of urinary IS levels (mmol/L, 2 standard errors). Signiﬁcan
methoxazole [Cotrim] until day 1, ciproﬂoxacin þ metronidazole day 1 until engra
in Table 3.antibiotics, induction of speciﬁc AMPs such as Reg3alpha
declines, which is the major peptide preventing enterococcal
overgrowth [15].
In addition, our data showed additional microbiome
shifts associated with GI GVHD, as enterococci were more
prominent in patients with subsequent and most prominent
and persistent in patients with active GI GVHD. Using an
indirect metabolomic approach, we observed similar inter-
ference of both antibiotics and, to a minor extent, GI GVHD
on urinary IS levels: The clear correlation of IS with
commensal bacteria such as E. rectale and Clostridia is in line
with the reported production of its precursor from trypto-
phan by colonic commensal bacteria [16].
Our study has limitations of sampling. It was difﬁcult to
extract sufﬁcient 16S rDNA for pyrosequencing from stool
specimens that had been collected from patients with
watery diarrhea during the neutropenic period. A further
limitation of the present study was its ability to capture only
relative rather than absolute changes in abundance of
enterococci in the GI tract. The existence of signiﬁcant dif-
ferences in absolute content of enterococci and other bac-
teria in the stool specimens investigated here is reﬂected by
the fact that it took in some cases up to 9 independent PCR
reactions to generate amounts of 16S rDNA sufﬁcient for
successful pyrosequencing analysis. Real-time quantitative
PCR of 16S rDNA would constitute an obvious means of
quantitating bacterial load but is hampered by the difﬁculty
of normalizing 16S rDNA content to such physical measures
as weight of stool specimens, which range in consistency
from purely liquid to mushy, semiformed, and formed. In-
direct measures, such as concentrations of serum or urine
biomarkers of bacterial metabolism, may provide an alter-
native for estimating gut bacterial load. Currently, however,t drop of IS levels in relation to antibiotic prophylaxis (trimethoprim/sulfa-
ftment [days 16 to 20]). Interaction of GVHD and antibiotic treatment is shown
Table 3
Mean IS Levels in Relation to Antibiotic Treatment and GI GVHD
Treatment Urinary IS
( Standard Error) mmol/L
Pre-SCT (n ¼ 14) 45.21 (9.10)
Post-SCT
Without antibiotics
No active GVHD (n ¼ 19) 28.24 (8.69)
With active GVHD (n ¼ 4) 6.97 (5.86)
With antibiotics
No active GI GVHD (n ¼ 60) 6.63 (2.15)
With active GI GVHD (n ¼ 7) .06 (.02)
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ciﬁc for enterococci. Decreased levels of IS in the urine
during the neutropenic period and after application of an-
tibiotics and even more in patients with GI GVHD suggest a
dramatic suppression of colonic commensals but do not
reveal any information on the abundance of enterococci in
the gut.
These observations may reﬂect to some extent the results
of 2 studies reporting a disruption of the intestinal micro-
biome in GVHD. In the murine study by Eriguchi et al. [8], a
loss of alpha-defensins as the major group of AMPs was re-
ported in mice developing intestinal GVHD. Jenq et al. [9]
tested the role of antibiotic pretreatment on both micro-
biome composition and the severity and outcome of GVHD.
All mice that developed intestinal GVHD revealed massive
changes in the intestinal microbiome. However, mice that
had not received antibiotics had an overgrowth of lactoba-
cilli, whereas ampicillin treatment resulted in a predominant
enterococcal ﬂora as observed in our patients. The murine
data suggested that changes in the intestinal microbiome
also directly inﬂuenced GVHD, as mice treated with ampi-
cillin had worse survival and an increased pathology score.
However, due to the limitations of sampling and quanti-
ﬁcation, the clinical data do not allow any causal conclusion
but may give rise to hypotheses worth testing. Direct analysis
of the mucosal microbiome might help to overcome the
limitation of insufﬁcient quantities of bacterial DNA, partic-
ularly in watery stools, and facilitate quantiﬁcation. In addi-
tion, more patients with active GI GVHD who do not receive
antibiotics need to be included to dissect effects originating
from antibiotics and GVHD. In an ongoing study, we are
analyzing patients who have been weaned off antibiotics for
several weeks before the onset of delayed acute GVHD. Pre-
liminary results of enterococcal PCR also suggest a substan-
tial shift to enterococci in a very high fraction of patients.
Direct contribution of enterococci to the worsening of
GVHD seems possible based on the aforementioned murine
data and may be caused by enterococcal epitheliolysins and
other toxins that inﬂict epithelial damage [17,18]. However,
because of the low load of bacteria in the aplastic period, it is
more likely that the observed predominance of enterococci is
rather an indicator of loss of bacterial diversity, as outlined in
Figure 1 This loss of diversity is ﬁrst induced by oral and
systemic broad-spectrum antibiotics, as clearly shown by the
substantial drop of IS levels. Additional contribution of GVHD
to loss of diversity seems possible not only on the basis of the
murine data but is also supported by our recent clinical
observation on a substantial loss of Paneth cells in biopsies
form patients with severe GI GVHD, which was also highly
predictive for outcome [19], and might be associated with
loss of AMPs. However, careful analyses of the AMPs in these
intestinal biopsies are needed to demonstrate a direct impactof Paneth cell defensins on microbiome composition in
GVHD patients.
Finally, the predominance of enterococci may diminish
the fraction of commensals, in particular various clostridial
strains considered to be important for maintaining tolerance
against the intestinal microbiome by inducing regulatory
T cells [20,21]. This also raises concerns regarding the prac-
tice of intestinal decontamination. Although complete
decontamination may be protective against GVHD, our
observation indicates that current protocols achieve incom-
plete rather than complete decontamination, which may be
the worst scenario. Deﬁning the role of the microbiome in
development of intestinal inﬂammation may help to develop
alternative approaches for prevention of intestinal GVHD
such as the use of speciﬁc probiotics or therapeutic appli-
cation of AMPs. Deﬁning inﬂammatory “checkpoints” of
GVHD, as described by Chakraverty et al. [22], related to
the microbiome may even contribute to better dissect the
deleterious effects associated with clinical GI GVHD from
graft-versus-host reactions needed for optimal graft-versus-
leukemia effects.ACKNOWLEDGMENTS
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